Current development in non-invasive glucose monitoring

Amaral, Carlos E. F. do; Wolf, Benjamin

doi:10.1016/j.medengphy.2007.06.003

Cited by 234 publications

(82 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this region the absorption peaks are sharper and more defined when compared with the broader weaker peaks seen in the NIR region. This is observed for both glucose and other compounds (Ferrante do Amaral & Wolf, 2008). However, hydration level of the skin can has a strong impact on such absorption signals and this is subject to variation.…”

Section: Mid-infrared Regionmentioning

confidence: 89%

“…The use of less invasive sensing methods for glucose are explored below, as an example of how minimally invasive monitoring is developing. Methods of noninvasive and continuous glucose monitoring are regularly reviewed (see for example Ferrante do Amaral & Wolf, 2008;Girardin et al, 2009;Pickup et al, 2005;Tura et al, 2007;Wickramasinghe et al, 2004) 3.5 Measurement of glucose in body fluids other than blood or interstitial fluid Although blood glucose concentrations are of interest, noninvasive methods for measuring glucose have been attempted using a number of different fluids in the body. The following discussion concentrates on fluids that are most readily accessible, such as sweat, saliva, tear fluid and urine while sampling of interstitial fluid will be discussed in later sections.…”

Section: Less Invasive Approaches To Health Monitoringmentioning

confidence: 99%

“…Secondly, the absorption coefficient of glucose is low in the near-infrared region and, finally, the spectral bands due to glucose overlap with bands due to water, fat, haemoglobin and proteins. This introduces significant technical challenges for signal sensitivity and signal interference, which will need to be addressed in order to demonstrate sufficient accuracy of glucose measurement (Pickup et al, 2005;Tura et al, 2007;Ferrante do Amaral & Wolf, 2008). The cost and physical size of equipment required for infrared spectroscopy measurements may also limit its application in continuous monitoring, particularly in the context of wearable sensors.…”

Section: Near-infrared Spectroscopy (Nir)mentioning

confidence: 99%

See 2 more Smart Citations

Minimally Invasive Sensing

McCormick¹,

Heath²,

Connolly³

2011

Biosensors - Emerging Materials and Applications

View full text Add to dashboard Cite

Section: Mid-infrared Regionmentioning

confidence: 89%

Section: Less Invasive Approaches To Health Monitoringmentioning

confidence: 99%

Section: Near-infrared Spectroscopy (Nir)mentioning

confidence: 99%

See 1 more Smart Citation

Minimally Invasive Sensing

McCormick¹,

Heath²,

Connolly³

2011

Biosensors - Emerging Materials and Applications

View full text Add to dashboard Cite

“…Attempts to accurately measure glucose, or at least predict its concentration from its effects on the body tissue, without a blood or tissue fluid sample, have been pursued as long as continuous sensor technology. While the promise of noninvasive glucose monitoring [43,44] remains a strong desire among PwD, the unremarkable spectroscopic characteristics of glucose and interfering physical and chemical properties have to date prevented achievement of the required performance. Nonenzymatic glucose sensors currently find application only in areas where specificity is not required, when no other reducing sugar is present, or when specificity is achieved through some previous process.…”

Section: Glucose Measurement Technologymentioning

confidence: 99%

Electrochemical Glucose Biosensors for Diabetes Care

Ocvirk¹,

Buck²,

DuVall³

2016

Trends in Bioelectroanalysis

View full text Add to dashboard Cite

Blood glucose monitoring (BGM) is the most successful application of electrochemical biosensor technology and has motivated tremendous improvements in biology, chemistry, measurement, and fabrication methods of biosensors. The performance of electrochemical biosensors used for BGM has improved greatly over the last four decades. Technological advance has allowed to measure blood glucose (BG) over a wide range of glucose concentration, a wide temperature and hematocrit range in the presence of an abundance of interfering substances with ever-increasing accuracy, and precision in minute sample volumes. The use of optimized enzymes, mediators, and electrochemical measurement methods enables this tremendous progress in performance. Continuous glucose monitoring (CGM) systems based on minimally invasive amperometric sensors, inserted into the subcutaneous tissue, have significantly improved over initial offerings over the last 15 years with regard to time of use, accuracy, reliability, and convenience due to a multitude of parallel advances: materials needed for enzyme immobilization, polymeric cover membranes, and biocompatible coatings needed to tackle the response by the complex body interface have been developed; wireless transfer and processing of unprecedented data volume have been established; effortless and painless insertion schemes of ever smaller sensors have been realized in order to overcome the concerns of persons with diabetes (PwDs) to use a minimally invasive sensor; and scalable manufacturing technologies of miniaturized minimally invasive sensors have allowed for ever improved reproducibility and increased production volume. Looking ahead, the demands on blood glucose system performance G. Ocvirk (*) Roche Diabetes Care GmbH, Mannheim, Germany e-mail: gregor.ocvirk@roche.com H. Buck and S.H. DuVall Roche Diabetes Care, Inc., Indianapolis, IN, USA e-mail: harvey.buck@roche.com; stacy.duvall@roche.com are expected to grow even as the pressures to lower the cost of systems increase. The drive for the future is to continue to push the limits on system performance under real-life conditions while lowering cost, all while finding ways to provide the best medical value to PwDs and healthcare providers. Technical issues of commercially available CGM sensors remain to be solved which currently impede reliable hypo-and hyperglycemic alarms, safe insulin dosing recommendations, or insulin pump control at any time of use. It is realistic to assume that continuous glucose monitoring (CGM) systems will be adopted in the future by a larger population of PwDs. Yet it is also clear that BGM systems will remain a major choice of the great majority of PwDs on a global scale. This review offers a technical overview about user, system, and major regulatory requirements and available suitable sensor technology and demonstrated performance of electrochemical BGM and CGM systems from an industrial R&D perspective.

show abstract

“…Currently, Systems which puncture the skin are standard techniques for selfmonitoring (6-7% accuracy) reading glucose concentrations at home through electrochemical, colorimetric or optical disposable strips for prick blood samples [1] in finger. The widespread use of finger-prick sampling has resulted in better day-to-day blood glucose control with a significant delay in the onset of complications associated with diabetes [2] .…”

Section: Introductionmentioning

confidence: 99%

An effective method based on reference point for glucose sensing at 1100-1600nm

Zheng

Yue

2011

SPIE Proceedings

View full text Add to dashboard Cite

Non-invasive blood glucose sensing by near-infrared spectroscopy is easily interrupted by the strong background variations compared to the weak glucose signals. In this work, according to the distribution of diffuse reflectance intensity at different source-detector separations, a method based on a reference point and a measuring point, where the diffuse reflectance intensity is insensitive and most sensitive to the variation of glucose concentration, respectively, is applied. And the data processing method based on the information of two points is investigated to improve the precision of glucose sensing. Based on the Monte Carlo simulation in 5% intralipid solution model, the corresponding optical probe is designed which includes two detecting points: a reference point located at 1.3-1.7mm and a measuring point located at 1.7-2.1mm. Using the probe, the in vitro experiment with different glucose concentrations in the intralipid solution is conducted at 1100-1600nm. As a result, compared to the PLS model built by the signal of the measuring point, the root mean square error of prediction (RMSEP) and root mean square error of cross calibration (RMSEC) of the corrected model built by reference point and measuring point reduces by 45.10%, and 32.15% respectively.

show abstract

Current development in non-invasive glucose monitoring

Cited by 234 publications

References 60 publications

Minimally Invasive Sensing

Minimally Invasive Sensing

Electrochemical Glucose Biosensors for Diabetes Care

An effective method based on reference point for glucose sensing at 1100-1600nm

Contact Info

Product

Resources

About